🚀 VC round data is live in beta, check it out!
Belite Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Belite Bio and similar public comparables like Laurus Labs, China Resources Sanjiu, Bachem, Arcellx and more.
Belite Bio Overview
About Belite Bio
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Founded
2018
HQ
Employees
20
Website
Sectors
Financials (LTM)
EV
$6B
Belite Bio Financials
Belite Bio reported last 12-month revenue of $8M and negative EBITDA of ($91M).
In the same LTM period, Belite Bio generated $5M in gross profit, ($91M) in EBITDA losses, and had net loss of ($78M).
Revenue (LTM)
Belite Bio P&L
In the most recent fiscal year, Belite Bio reported revenue of — and EBITDA of ($77M).
Belite Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($91M) | XXX | ($77M) | XXX | XXX | XXX |
| EBITDA Margin | (1179%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (1115%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($78M) | XXX | ($78M) | XXX | XXX | XXX |
| Net Margin | (1022%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Belite Bio Stock Performance
Belite Bio has current market cap of $7B, and enterprise value of $6B.
Market Cap Evolution
Belite Bio's stock price is $165.59.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $7B | 0.0% | XXX | XXX | XXX | $-1.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBelite Bio Valuation Multiples
Belite Bio trades at 797.7x EV/Revenue multiple, and (67.6x) EV/EBITDA.
EV / Revenue (LTM)
Belite Bio Financial Valuation Multiples
As of April 19, 2026, Belite Bio has market cap of $7B and EV of $6B.
Equity research analysts estimate Belite Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Belite Bio has a P/E ratio of (84.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 797.7x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (67.6x) | XXX | (79.4x) | XXX | XXX | XXX |
| EV/EBIT | (71.5x) | XXX | (72.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 1126.2x | XXX | — | XXX | XXX | XXX |
| P/E | (84.4x) | XXX | (85.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (164.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Belite Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Belite Bio Margins & Growth Rates
Belite Bio's revenue in the last 12 month grew by 929%.
Belite Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $4.2M for the same period.
Belite Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 929% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (1179%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (32%) | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $4.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 611% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 633% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Belite Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Belite Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Laurus Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| China Resources Sanjiu | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcellx | XXX | XXX | XXX | XXX | XXX | XXX |
| Protagonist Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Belite Bio M&A Activity
Belite Bio acquired XXX companies to date.
Last acquisition by Belite Bio was on XXXXXXXX, XXXXX. Belite Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Belite Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBelite Bio Investment Activity
Belite Bio invested in XXX companies to date.
Belite Bio made its latest investment on XXXXXXXX, XXXXX. Belite Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Belite Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Belite Bio
| When was Belite Bio founded? | Belite Bio was founded in 2018. |
| Where is Belite Bio headquartered? | Belite Bio is headquartered in United States. |
| How many employees does Belite Bio have? | As of today, Belite Bio has over 20 employees. |
| Who is the CEO of Belite Bio? | Belite Bio's CEO is Yu-Hsin Lin. |
| Is Belite Bio publicly listed? | Yes, Belite Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Belite Bio? | Belite Bio trades under BLTE ticker. |
| When did Belite Bio go public? | Belite Bio went public in 2022. |
| Who are competitors of Belite Bio? | Belite Bio main competitors are Laurus Labs, China Resources Sanjiu, Bachem, Arcellx. |
| What is the current market cap of Belite Bio? | Belite Bio's current market cap is $7B. |
| What is the current revenue of Belite Bio? | Belite Bio's last 12 months revenue is $8M. |
| What is the current revenue growth of Belite Bio? | Belite Bio revenue growth (NTM/LTM) is 929%. |
| What is the current EV/Revenue multiple of Belite Bio? | Current revenue multiple of Belite Bio is 797.7x. |
| Is Belite Bio profitable? | No, Belite Bio is not profitable. |
| What is the current EBITDA of Belite Bio? | Belite Bio has negative EBITDA and is not profitable. |
| What is Belite Bio's EBITDA margin? | Belite Bio's last 12 months EBITDA margin is (1179%). |
| What is the current EV/EBITDA multiple of Belite Bio? | Current EBITDA multiple of Belite Bio is (67.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.